Eledon Pharmaceuticals (ELDN) Accounts Payables (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Accounts Payables data on file, last reported at $6.6 million in Q1 2026.

• Quarterly Accounts Payables rose 126.99% year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 million (up 126.99% YoY) and the FY2025 annual result came in at $3.6 million, down 37.82% from the prior year.
• Accounts Payables climbed to $6.6 million in Q1 2026, from $3.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $6.6 million in Q1 2026 to a low of $465000.0 in Q3 2023.
• A 5-year average of $3.2 million and a median of $2.9 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2023 — Accounts Payables tumbled 87.95% — and 2024, when it surged 1160.22%.
• Tracing ELDN's Accounts Payables over 5 years: stood at $2.2 million in 2022, then sank by 56.05% to $967000.0 in 2023, then surged by 503.21% to $5.8 million in 2024, then plunged by 37.82% to $3.6 million in 2025, then soared by 81.56% to $6.6 million in 2026.
• The last three Accounts Payables figures came in at $6.6 million (Q1 2026), $3.6 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.